AstraZeneca to carve out antibiotic R&D into separate firm
February 27, 2015 at 03:21 AM EST
LONDON (Reuters) - Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy areas.